TEDDM2P

Across TCGA pan-cancer cohorts, TEDDM2P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of TEDDM2P’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TEDDM2P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TEDDM2P is over-expressed in tumor.

LIHC, BRCA, and LUSC are the cancer types where TEDDM2P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TEDDM2P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.369	.007	4	view →
BRCA	All	All	+0.028	<.001	4	view →
LUSC	Male	All	+0.042	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

TEDDM2P–LIHC

Open the LIHC breakdown →